Targeting the sympathetic nervous system with the selective imidazoline receptor agonist moxonidine for the management of hypertension: an international position statement.
Journal
Journal of hypertension
ISSN: 1473-5598
Titre abrégé: J Hypertens
Pays: Netherlands
ID NLM: 8306882
Informations de publication
Date de publication:
15 May 2024
15 May 2024
Historique:
medline:
15
5
2024
pubmed:
15
5
2024
entrez:
15
5
2024
Statut:
aheadofprint
Résumé
Hypertension is often linked with metabolic risk factors that share common pathophysiological pathways. Despite wide-spread availability of multiple drug classes, optimal blood pressure (BP) control remains challenging. Increased central sympathetic outflow is frequently neglected as a critical regulator of both circulatory and metabolic pathways and often remains unopposed therapeutically. Selective imidazoline receptor agonists (SIRAs) effectively reduce BP with a favorable side effect profile compared with older centrally acting antihypertensive drugs. Hard outcome data in hypertension, such as prevention of stroke, heart and kidney diseases, are not available with SIRAs. However, in direct comparisons, SIRAs were as effective as angiotensin-converting enzyme inhibitors, β-blockers, calcium channel blockers, and diuretics in lowering BP. Other beneficial effects on metabolic parameters in hypertensive patients with concomitant overweight and obesity have been documented with SIRAs. Here we review the existing evidence on the safety and efficacy of moxonidine, a widely available SIRA, compared with common antihypertensive agents and provide a consensus position statement based on inputs from 12 experts from Europe and Australia on SIRAs in hypertension management.
Identifiants
pubmed: 38747424
doi: 10.1097/HJH.0000000000003769
pii: 00004872-990000000-00471
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Références
Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365:217–223.
NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet 2021; 398:957–980.
Kannel WB. Risk stratification in hypertension: new insights from the Framingham Study. Am J Hypertens 2000; 13 (1 pt 2):3S–10S.
Mancia G, Kreutz R, Brunström M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH). J Hypertens 2023; 41:1874–2071.
Nguyen Q, Dominguez J, Nguyen L, Gullapalli N. Hypertension management: an update. Am Health Drug Benefits 2010; 3:47–56.
World Health Organization. Hypertension. Available at: https://www.who.int/news-room/fact-sheets/detail/hypertension#:∼:text=Approximately%201%20in%205%20adults,cause%20of%20premature%20death%20worldwide. [Accessed 28 March 2023]
Schutte AE, Webster R, Jennings G, Schlaich MP. Uncontrolled blood pressure in Australia: a call to action. Med J Aust 2022; 216:61–63.
Kotsis V, Nilsson P, Grassi G, Mancia G, Redon J, Luft F, et al. WG on Obesity, Diabetes, the High Risk Patient, European Society of Hypertension. New developments in the pathogenesis of obesity-induced hypertension. J Hypertens 2015; 33:1499–1508.
Carnagarin R, Tan K, Adams L, Matthews VB, Kiuchi MG, Marisol Lugo Gavidia L, et al. Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)-a condition associated with heightened sympathetic activation. Int J Mol Sci 2021; 22:4241.
Kiuchi MG, Ho JK, Nolde JM, Gavidia LML, Carnagarin R, Matthews VB, Schlaich MP, et al. Sympathetic activation in hypertensive chronic kidney disease - a stimulus for cardiac arrhythmias and sudden cardiac death? Front Physiol 2020; 10:1546.
Carnagarin R, Lambert GW, Kiuchi MG, Nolde JM, Matthews VB, Eikelis N, et al. Effects of sympathetic modulation in metabolic disease. Ann N Y Acad Sci 2019; 1454:80–89.
Lambert EA, Esler MD, Schlaich MP, Dixon J, Eikelis N, Lambert GW. Obesity-associated organ damage and sympathetic nervous activity. Hypertension 2019; 73:1150–1159.
Carnagarin R, Matthews VB, Herat LY, Ho JK, Schlaich MP. Autonomic regulation of glucose homeostasis: a specific role for sympathetic nervous system activation. Curr Diab Rep 2018; 18:107.
Carnagarin R, Matthews V, Zaldivia MTK, Peter K, Schlaich MP. The bidirectional interaction between the sympathetic nervous system and immune mechanisms in the pathogenesis of hypertension. Br J Pharmacol 2019; 176:1839–1852.
Carnagarin R, Matthews V, Gregory C, Schlaich MP. Pharmacotherapeutic strategies for treating hypertension in patients with obesity. Expert Opin Pharmacother 2018; 19:643–651.
Thorp AA, Schlaich MP. Relevance of sympathetic nervous system activation in obesity and metabolic syndrome. J Diabetes Res 2015; 2015:341583.
Schlaich M, Straznicky N, Lambert E, Lambert G. Metabolic syndrome: a sympathetic disease? Lancet Diabetes Endocrinol 2015; 3:148–157.
Beevers G, Lip GY, O’Brien E. ABC of hypertension: the pathophysiology of hypertension. BMJ 2001; 322:912–916.
Valensi P. Autonomic nervous system activity changes in patients with hypertension and overweight: role and therapeutic implications. Cardiovasc Diabetol 2021; 20:170.
Redon J, Cifkova R, Laurent S, Nilsson P, Narkiewicz K, Erdine S, Mancia G. Scientific Council of the European Society of Hypertension. The metabolic syndrome in hypertension: European society of hypertension position statement. J Hypertens 2008; 26:1891–1900.
Katsimardou A, Imprialos K, Stavropoulos K, Sachinidis A, Doumas M, Athyros V. Hypertension in metabolic syndrome: novel insights. Curr Hypertens Rev 2020; 16:12–18.
Macut D, Mladenović V, Bjekić-Macut J, Livadas S, Stanojlović O, Hrnčić D, et al. Hypertension in polycystic ovary syndrome: novel insights. Curr Hypertens Rev 2020; 16:55–60.
Leuzzi C, Modena MG. Hypertension in postmenopausal women: pathophysiology and treatment. High Blood Press Cardiovasc Prev 2011; 18:13–18.
Lambert EA, Teede H, Sari CI, Jona E, Shorakae S, Woodington K, et al. Sympathetic activation and endothelial dysfunction in polycystic ovary syndrome are not explained by either obesity or insulin resistance. Clin Endocrinol (Oxf) 2015; 83:812–819.
Schlaich MP, Straznicky N, Grima M, Ika-Sari C, Dawood T, Mahfoud F, et al. Renal denervation: a potential new treatment modality for polycystic ovary syndrome? J Hypertens 2011; 29:991–996.
Kim JM, Kim TH, Lee HH, Lee SH, Wang T. Postmenopausal hypertension and sodium sensitivity. J Menopausal Med 2014; 20:1–6.
Somers VK, Dyken ME, Clary MP, Abboud FM. Sympathetic neural mechanisms in obstructive sleep apnea. J Clin Invest 1995; 96:1897–1904.
Wolk R, Shamsuzzaman AS, Somers VK. Obesity, sleep apnea, and hypertension. Hypertension 2003; 42:1067–1074.
Kasiakogias A, Tsioufis C, Thomopoulos C, Aragiannis D, Alchanatis M, Tousoulis D, et al. Effects of continuous positive airway pressure on blood pressure in hypertensive patients with obstructive sleep apnea: a 3-year follow-up. J Hypertens 2013; 31:352–360.
McEvoy RD, Antic NA, Heeley E, Luo Y, Ou Q, Zhang X, et al. SAVE Investigators and Coordinators. CPAP for prevention of cardiovascular events in obstructive sleep apnea. N Engl J Med 2016; 375:919–931.
Pugh D, Gallacher PJ, Dhaun N. Management of hypertension in chronic kidney disease. Drugs 2019; 79:365–379.
Grassi G, Biffi A, Seravalle G, Bertoli S, Airoldi F, Corrao G, et al. Sympathetic nerve traffic overactivity in chronic kidney disease: a systematic review and meta-analysis. J Hypertens 2021; 39:408–416.
Hall JE, do Carmo JM, da Silva AA, Wang Z, Hall ME. Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. Circ Res 2015; 116:991–1006.
Tsioufis C, Georgiopoulos G, Oikonomou D, Thomopoulos C, Katsiki N, Kasiakogias A, et al. Hypertension and heart failure with preserved ejection fraction: connecting the dots. Curr Vasc Pharmacol 2018; 16:15–22.
Finks SW, Rumbak MJ, Self TH. Treating hypertension in chronic obstructive pulmonary disease. New Engl J Med 2020; 382:353–363.
Manolis AJ, Poulimenos LE, Kallistratos MS, Gavras I, Gavras H. Sympathetic overactivity in hypertension and cardiovascular disease. Curr Vasc Pharmacol 2014; 12:4–15.
Siddiqui M, Dudenbostel T, Calhoun DA. Resistant and refractory hypertension: antihypertensive treatment resistance vs treatment failure. Can J Cardiol 2016; 32:603–606.
Pathak A, Mrabeti S. β-blockade for patients with hypertension, ischemic heart disease or heart failure: where are we now? Vasc Health Risk Manag 2021; 17:337–348.
Deedwania P. Hypertension, dyslipidemia, and insulin resistance in patients with diabetes mellitus or the cardiometabolic syndrome: benefits of vasodilating (-blockers. J Clin Hypertens (Greenwich) 2011; 13:52–59.
Kountz DS. Are tolerability concerns a class effect of beta-blockers in treating patients with hypertension? Postgrad Med 2009; 121:14–24.
van Zwieten PA. Centrally acting antihypertensive drugs. Present and future. Clin Exp Hypertens 1999; 21:859–873.
Shetty S, Bhoraskar A, Mohan JC, Chafekar D, Tripathi K, Sivalingam M, et al. Selective imidazoline receptor agonists: redefining the role of centrally acting agents in management of hypertension. Int J Adv Med 2019; 6:1688–1694.
Sica DA. Centrally acting antihypertensive agents: an update. J Clin Hypertens (Greenwich) 2007; 9:399–405.
Lumb PJ, McMahon Z, Chik G, Wierzbicki AS. Effect of moxonidine on lipid subfractions in patients with hypertension. Int J Clin Pract 2004; 58:465–468.
Abellán J, Leal M, Hernández-Menárguez F, García-Galbis JA, Martínez-Pastor A, de Vinuesa SG, Luño J. Efficacy of moxonidine in the treatment of hypertension in obese, noncontrolled hypertensive patients. Kidney Int Suppl 2005; 93:S20–S24.
Elisaf MS, Petris C, Bairaktari E, Karabina SA, Tzallas C, Tselepis A, Siamopoulos KC. The effect of moxonidine on plasma lipid profile and on LDL subclass distribution. J Hum Hypertens 1999; 13:781–785.
Mitrovic V, Patyna W, Hüting J, Schlepper M. Hemodynamic and neurohumoral effects of moxonidine in patients with essential hypertension. Cardiovasc Drugs Ther 1991; 5:967–972.
Sharma AM, Wagner T, Marsalek P. Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study. J Hum Hypertens 2004; 18:669–675.
Ebinç H, Ozkurt ZN, Ebinç FA, Ucardag D, Caglayan O, Yilmaz M. Effects of sympatholytic therapy with moxonidine on serum adiponectin levels in hypertensive women. J Int Med Res 2008; 36:80–87.
Greenwood JP, Scott EM, Stoker JB, Mary DA. Chronic I(1)-imidazoline agonism: sympathetic mechanisms in hypertension. Hypertension 2000; 35:1264–1269.
Chazova I, Schlaich MP. Improved hypertension control with the imidazoline agonist moxonidine in a multinational metabolic syndrome population: principal results of the MERSY Study. Int J Hypertens 2013; 2013:541689.
Wenzel RR, Spieker L, Qui S, Shaw S, Lüscher TF, Noll G. I1-imidazoline agonist moxonidine decreases sympathetic nerve activity and blood pressure in hypertensives. Hypertension 1998; 32:1022–1027.
Kirch W, Hutt HJ, Plänitz V. Pharmacodynamic action and pharmacokinetics of moxonidine after single oral administration in hypertension patients. J Clin Pharmacol 1990; 30:1088–1095.
Schrover IM, Dorresteijn JAN, Smits JE, Danser AHJ, Visseren FLJ, Spiering W. Identifying treatment response to antihypertensives in patients with obesity-related hypertension. Clin Hypertens 2017; 23:20.
Dorresteijn JA, Schrover IM, Visseren FL, Scheffer PG, Oey PL, Danser AH, et al. Differential effects of renin-angiotensin-aldosterone system inhibition, sympathoinhibition and diuretic therapy on endothelial function and blood pressure in obesity-related hypertension: a double-blind, placebo-controlled cross-over trial. J Hypertens 2013; 31:393–403.
Kaaja R, Kujala S, Manhem K, Katzman P, Kibarskis A, Antikainen R, et al. Effects of sympatholytic therapy on insulin sensitivity indices in hypertensive postmenopausal women. Int J Clin Pharmacol Ther 2007; 45:394–401.
Frei M, Küster L, Gardosch von Krosigk PP, Koch HF, Küppers H. Moxonidine and hydrochlorothiazide in combination: a synergistic antihypertensive effect. J Cardiovasc Pharmacol 1994; 24 Suppl 1:S25–S28.
Kujala SM, Pöyhönen-Alho M, Kaaja RJ. Effects of sympatholytic therapy on postmenopausal symptoms in hypertensive postmenopausal women. Climacteric 2014; 17:356–362.
Pöyhönen-Alho MK, Manhem K, Katzman P, Kibarskis A, Antikainen RL, Erkkola RU, et al. Central sympatholytic therapy has anti-inflammatory properties in hypertensive postmenopausal women. J Hypertens 2008; 26:2445–2449.
Prichard BN, Simmons R, Rooks MJ, Haworth DA, Laws D, Wonnacott S. A double-blind comparison of moxonidine and atenolol in the management of patients with mild-to-moderate hypertension. J Cardiovasc Pharmacol 1992; 20:S45–S49.
Masajtis-Zagajewska A, Majer J, Nowicki M. Effect of moxonidine and amlodipine on serum YKL-40, plasma lipids and insulin sensitivity in insulin-resistant hypertensive patients-a randomized, crossover trial. Hypertens Res 2010; 33:348–353.
Sanjuliani AF, de Abreu VG, Francischetti EA. Selective imidazoline agonist moxonidine in obese hypertensive patients. Int J Clin Pract 2006; 60:621–629.
Plänitz V. Comparison of moxonidine and clonidine HCl in treating patients with hypertension. J Clin Pharmacol 1987; 27:46–51.
Plänitz V. Crossover comparison of moxonidine and clonidine in mild to moderate hypertension. Eur J Clin Pharmacol 1984; 27:147–152.
Prichard BN, Jäger BA, Luszick JH, Küster LJ, Verboom CN, Hughes PR, et al. Placebo-controlled comparison of the efficacy and tolerability of once-daily moxonidine and enalapril in mild to moderate essential hypertension. Blood Press 2002; 11:166–172.
Küppers HE, Jäger BA, Luszick JH, Gräve MA, Hughes PR, Kaan EC. Placebo-controlled comparison of the efficacy and tolerability of once-daily moxonidine and enalapril in mild-to-moderate essential hypertension. J Hypertens 1997; 15:93–97.
Martina B, Surber C, Jakobi C, Sponagel L, Gasser P. Effect of moxonidine and cilazapril on microcirculation as assessed by finger nailfold capillaroscopy in mild-to-moderate hypertension. Angiology 1998; 49:897–901.
Derosa G, Cicero AF, D’Angelo A, Fogari E, Salvadeo S, Gravina A, et al. Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial. Clin Ther 2007; 29:602–610.
Jacob S, Klimm HJ, Rett K, Helsberg K, Häring HU, Gödicke J. Effects of moxonidine vs. metoprolol on blood pressure and metabolic control in hypertensive subjects with type 2 diabetes. Exp Clin Endocrinol Diabetes 2004; 112:315–322.
Wolf R. The treatment of hypertensive patients with a calcium antagonist or moxonidine: a comparison. J Cardiovasc Pharmacol 1992; 20:S42–S44.
Schlaich MP, Lambert E, Kaye DM, Krozowski Z, Campbell DJ, Lambert G, et al. Sympathetic augmentation in hypertension: role of nerve firing, norepinephrine reuptake, and angiotensin neuromodulation. Hypertension 2004; 43:169–175.
Esler M, Jennings G, Lambert G, Meredith I, Horne M, Eisenhofer G. Overflow of catecholamine neurotransmitters to the circulation: source, fate, and functions. Physiol Rev 1990; 70:963–985.
Neutel JM. The role of combination therapy in the management of hypertension. Nephrol Dial Transplant 2006; 21:1469–1473.
Schlaich MP, Almahmeed W, Arnaout S, Prabhakaran D, Zhernakova J, Zvartau N, Schutte AE. The role of selective imidazoline receptor agonists in modern hypertension management: an international real-world survey (STRAIGHT). Curr Med Res Opin 2020; 36:1939–1945.
Fenton C, Keating GM, Lyseng-Williamson KA. Moxonidine. Drugs 2006; 66:477–496.
Frei M, Kuster L, Gardosch von Krosigk PP, Koch HF, Küppers H. Moxonidine and hydrochlorothiazide in combination: a synergistic antihypertensive effect. J Cardiovasc Pharmacol 1994; 24:S25–S28.
Waters J, Ashford J, Jäger B, Verboom CN, Wonnacott S. Use of moxonidine as initial therapy and in combination in the treatment of essential hypertension-results of the TOPIC (Trial Of Physiotens In Combination) Study. J Clin Basic Cardiol 1999; 2:219–224.
Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351:1755–1762.
Cohn JN, Pfeffer MA, Rouleau J, Sharpe N, Swedberg K, Straub M, et al. MOXCON Investigators. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail 2003; 5:659–667.